3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Multiple Myeloma
9
Recurrence
5
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myeloid, Acute
3
Sarcoma
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Vascular Neoplasms
1
Triple Negative Breast Neoplasms
1
Solitary Fibrous Tumors
1
Solid Tumor Malignancy
1
Smooth Muscle Tumor
1
Sarcoma, Clear Cell
1
Recurrent Squamous Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibrosarcoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms, Adipose Tissue
1
Neoplasm Metastasis
1
Myoepithelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Interventions
Cetuximab
44
Oxaliplatin
39
Irinotecan
38
Fluorouracil
36
Capecitabine
36
pembrolizumab
35
Leucovorin
35
Bevacizumab
35
Nivolumab
21
Gemcitabine
17
regorafenib
13
Panitumumab
12
IFL protocol
12
Folfox protocol
12
Cyclophosphamide
12
Pemetrexed
11
Cisplatin
11
tislelizumab
9
Paclitaxel
9
HMPL-013
9
Carboplatin
9
130-nm albumin-bound paclitaxel
8
durvalumab
7
Specimen Handling
7
Docetaxel
7
trametinib
6
Trifluridine
6
Ipilimumab
6
Drug Therapy
6
trifluridine tipiracil drug combination
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colorectal Neoplasms
×
selinexor
×
Clear all
NCT04256707
2025-03-19
SPRINT
Karyopharm Therapeutics Inc
Phase 1/2
Completed
126 enrolled